SCHEMBL23237307

SCHEMBL23237307

Cc1ccc([C@@H](O)CC#N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
ALDH1A1 P00352 6/20 0.40
MAPT P10636 2/20 0.40
CYP2A6 P11509 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
CHRNA7 P36544 1/20 0.35
ACHE P22303 1/20 0.35
ALOX5 P09917 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
PGR P06401 1/20 0.35
HTR1A P08908 1/20 0.34
THPO P40225 1/20 0.34
BLM P54132 1/20 0.34
NMUR2 Q9GZQ4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977775 1.00 ESR1 (0.42) ESR1ESR2ALDH1A1MAPTCYP2A6
SCHEMBL4977780 1.00 ESR1 (0.42) ESR1ESR2ALDH1A1MAPTCYP2A6
SCHEMBL18704051 0.83 ESR1 (0.38) ESR1ESR2ALDH1A1LMNASMN1; SMN2
SCHEMBL8764025 0.80 ESR1 (0.50) ESR1ESR2ALDH1A1MAPTCYP2A6
SCHEMBL24681202 0.79 ESR1 (0.38) ESR1ESR2ALDH1A1LMNASMN1; SMN2
SCHEMBL23237367 0.79 AOC3 (0.47) ESR1ESR2ALDH1A1LMNASMN1; SMN2
SCHEMBL23209157 0.79 AOC3 (0.47) ESR1ESR2ALDH1A1LMNASMN1; SMN2
SCHEMBL18704243 0.79 AOC3 (0.47) ESR1ESR2ALDH1A1LMNASMN1; SMN2
SCHEMBL2547851 0.79 IGF1R (0.38) ESR1ESR2ALOX5MEN1KMT2A
SCHEMBL7933326 0.79 AOC3 (0.47) ESR1ESR2ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-02 US disclosed
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-02 US disclosed
US-20220340590-A1 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-10-27 US disclosed
WO-2022219012-A1 3H,4H,5H,6H,7H-PYRIMIDO[4,5-B][1,4]OXAZINE-4,6-DIONE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-10-20 WO disclosed
WO-2022219013-A1 URACIL DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-10-20 WO disclosed
US-11136336-B2 Thienopyrimidones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-10-05 US disclosed
WO-2021074196-A1 THIENOPYRIMIDONES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-04-22 WO disclosed
US-20210107918-A1 Novel Thienopyrimidones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107918-A1 Novel Thienopyrimidones TRPA1, TRPV1, TRPV2 ESR1 3304/4885ESR2 2207/4885ALDH1A1 1108/4885
US-20220340590-A1 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV3 ESR1 2852/4885ESR2 2041/4885ALDH1A1 500/4885
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors TRPA1, TRPV1, TRPM6 ESR1 3742/4885ESR2 3941/4885ALDH1A1 222/4885
US-11136336-B2 Thienopyrimidones TRPA1, TRPV1, TRPV2 ESR1 3568/4885ESR2 2507/4885ALDH1A1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.